TY - JOUR
T1 - Arrhythmias in Pregnancy
AU - Tamirisa, Kamala P.
AU - Elkayam, Uri
AU - Briller, Joan E.
AU - Mason, Pamela K.
AU - Pillarisetti, Jayasree
AU - Merchant, Faisal M.
AU - Patel, Hena
AU - Lakkireddy, Dhanunjaya R.
AU - Russo, Andrea M.
AU - Volgman, Annabelle Santos
AU - Vaseghi, Marmar
N1 - Publisher Copyright:
© 2022 American College of Cardiology Foundation
PY - 2022/1
Y1 - 2022/1
N2 - Increasing maternal mortality and incidence of arrhythmias in pregnancy have been noted over the past 2 decades in the United States. Pregnancy is associated with a greater risk of arrhythmias, and patients with a history of arrhythmias are at significant risk of arrhythmia recurrence during pregnancy. The incidence of atrial fibrillation in pregnancy is rising. This review discusses the management of tachyarrhythmias and bradyarrhythmias in pregnancy, including management of cardiac arrest. Management of fetal arrhythmias are also reviewed. For patients without structural heart disease, β-blocker therapy, especially propranolol and metoprolol, and antiarrhythmic drugs, such as flecainide and sotalol, can be safely used to treat tachyarrhythmias. As a last resort, catheter ablation with minimal fluoroscopy can be performed. Device implantation can be safely performed with minimal fluoroscopy and under echocardiographic or ultrasound guidance in patients with clear indications for devices during pregnancy. Because of rising maternal mortality in the United States, which is partly driven by increasing maternal age and comorbidities, a multidisciplinary and/or integrative approach to arrhythmia management from the prepartum to the postpartum period is needed.
AB - Increasing maternal mortality and incidence of arrhythmias in pregnancy have been noted over the past 2 decades in the United States. Pregnancy is associated with a greater risk of arrhythmias, and patients with a history of arrhythmias are at significant risk of arrhythmia recurrence during pregnancy. The incidence of atrial fibrillation in pregnancy is rising. This review discusses the management of tachyarrhythmias and bradyarrhythmias in pregnancy, including management of cardiac arrest. Management of fetal arrhythmias are also reviewed. For patients without structural heart disease, β-blocker therapy, especially propranolol and metoprolol, and antiarrhythmic drugs, such as flecainide and sotalol, can be safely used to treat tachyarrhythmias. As a last resort, catheter ablation with minimal fluoroscopy can be performed. Device implantation can be safely performed with minimal fluoroscopy and under echocardiographic or ultrasound guidance in patients with clear indications for devices during pregnancy. Because of rising maternal mortality in the United States, which is partly driven by increasing maternal age and comorbidities, a multidisciplinary and/or integrative approach to arrhythmia management from the prepartum to the postpartum period is needed.
KW - arrhythmias
KW - fetal
KW - peripartum
KW - pregnancy
UR - http://www.scopus.com/inward/record.url?scp=85122500271&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122500271&partnerID=8YFLogxK
U2 - 10.1016/j.jacep.2021.10.004
DO - 10.1016/j.jacep.2021.10.004
M3 - Review article
C2 - 35057977
AN - SCOPUS:85122500271
SN - 2405-500X
VL - 8
SP - 120
EP - 135
JO - JACC: Clinical Electrophysiology
JF - JACC: Clinical Electrophysiology
IS - 1
ER -